These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 7026249)
41. Torsade des pointes and aprindine. Sideris DA; Kontoyannis DA; Moulopoulos SD Int J Cardiol; 1985 Apr; 7(4):413-6. PubMed ID: 2580805 [TBL] [Abstract][Full Text] [Related]
42. Preliminary experience in the treatment of cardiac arrhythmias with aprindine. Bollen G; Enderle J Acta Cardiol; 1974; Suppl 18():355-60. PubMed ID: 4138528 [No Abstract] [Full Text] [Related]
43. Pharmacological evaluation of aprindine (AC 1802) a new antiarrhythmic agent. Georges A; Hosslet A; Duvernay G Acta Cardiol; 1973; 28(2):166-91. PubMed ID: 4540792 [No Abstract] [Full Text] [Related]
44. [Comparison of the anti-arrhythmic effects of propafenone and aprindine in the treatment of refractory chronic ventricular arrhythmias. A randomized double-blind crossover study controlled with placebo]. Purcaro A; Amici R; Ciampani N; Costantini C; Mocchegiani R; Pigini G G Ital Cardiol; 1983; 13(6):444-50. PubMed ID: 6357929 [TBL] [Abstract][Full Text] [Related]
45. [Treatment of extrasystoles using a new oral anti-arrhythmic agent Aprindine]. Sterz H Acta Med Austriaca; 1974; 1(4):127-31. PubMed ID: 4142916 [No Abstract] [Full Text] [Related]
46. [Fatal agranulocytosis induced by aprindine]. García Saavedra V; Peró Silva A; Llorente A; Richart C Rev Clin Esp; 1989; 185(3):169. PubMed ID: 2623233 [No Abstract] [Full Text] [Related]
47. The efficacy of intravenous moxaprindine on ventricular ectopic activity. Waleffe A; Guillaume D; Mary-Rabine L; Kulbertus H Acta Cardiol; 1980; 35(4):257-68. PubMed ID: 6971032 [TBL] [Abstract][Full Text] [Related]
52. Suppression of refractory arrhythmias by aprindine in patients with the Wolff-Parkinson-White syndrome. Reid PR; Greene HL; Varghese PJ Br Heart J; 1977 Dec; 39(12):1353-60. PubMed ID: 603737 [TBL] [Abstract][Full Text] [Related]
53. Drug corner. Aprindine (Fibocil). Crumpley L Crit Care Nurse; 1982; 2(5):20, 23. PubMed ID: 6924868 [No Abstract] [Full Text] [Related]
54. [Agranulocytosis caused by aprindine. Apropos of a new case]. González Juanatey JR; Amaro Cendon A; Pose Reino A; Torre Carballada A; Rubio Alvarez J; Gil de la Peña M Med Clin (Barc); 1984 May; 82(19):865-6. PubMed ID: 6738221 [No Abstract] [Full Text] [Related]
55. [Agranulocytosis during use of aprindine]. van Leeuwen R Ned Tijdschr Geneeskd; 1976 Sep; 120(36):1549-50. PubMed ID: 967294 [No Abstract] [Full Text] [Related]
56. [Effects of aprindine on the induction and termination of supraventricular tachycardia in patients with accessory pathway syndrome]. Kubota K; Ikeda T; Takata S; Murakami T; Nakamura S; Fujiki A; Higashino A; Hattori N Kokyu To Junkan; 1985 Jul; 33(7):913-9. PubMed ID: 4059681 [No Abstract] [Full Text] [Related]
57. Aprindine treatment of recurrent ventricular tachycardia in patients with mitral valve prolapse. Troup PJ; Zipes DP Am Heart J; 1979 Mar; 97(3):322-8. PubMed ID: 420071 [No Abstract] [Full Text] [Related]
58. Suppression of the repetitive ventricular response: an index of long-term antiarrhythmic effectiveness of aprindine for ventricular tachycardia in man. Schaeffer AH; Greene HL; Reid PR Am J Cardiol; 1978 Dec; 42(6):1007-12. PubMed ID: 727128 [TBL] [Abstract][Full Text] [Related]
59. Ventricular tachycardia: prediction of response to oral aprindine with intravenous aprindine. Strasberg B; Palileo E; Prechel D; Bauernfeind R; Swiryn S; Wyndham CR; Dhingra RC; Kehoe R; Rosen KM Am J Cardiol; 1981 Mar; 47(3):676-82. PubMed ID: 6781325 [TBL] [Abstract][Full Text] [Related]
60. [Aprindine in the treatment of chronic premature ventricular contractions. Evaluations based on the two-way analysis of variance and linear regression analysis]. Oyama Y; Kanda K; Kawasaki H Kokyu To Junkan; 1986 Mar; 34(3):309-13. PubMed ID: 2422714 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]